Silvia Colucci

List of Publications by Year
in descending order

122 papers	6,242 citations	53660 45 h-index	76769 74 g-index
124 all docs	124 docs citations	124 times ranked	7202 citing authors

#	Article	IF	Citations
1	FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective. International Journal of Molecular Sciences, 2021, 22, 1605.	1.8	61
2	The genetic background and vitamin D supplementation can affect irisin levels in Praderâ€“Willi syndrome. Journal of Endocrinological Investigation, 2021, 44, 2261-2271.	1.8	11
3	The Myokine Irisin Promotes Osteogenic Differentiation of Dental Bud-Derived MSCs. Biology, 2021, 10, 295.	1.3	20
4	The Novel Role of PGC1Î± in Bone Metabolism. International Journal of Molecular Sciences, 2021, 22, 4670.	1.8	12
5	LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Nonâ€small Cell Lung Cancer Patients. Journal of Bone and Mineral Research, 2020, 35, 671-680.	3.1	31
6	Irisin Prevents Disuseâ€induced Osteocyte Apoptosis. Journal of Bone and Mineral Research, 2020, 35, 766-775.	3.1	82
7	Irisin prevents microgravityâ€induced impairment of osteoblast differentiation in vitro during the space flight CRSâ€14 mission. FASEB Journal, 2020, 34, 10096-10106.	0.2	38
8	Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases. Current Osteoporosis Reports, 2020, 18, 401-407.	1.5	28
9	Shedding â€œLIGHTâ€•on the Link between Bone and Fat in Obese Children and Adolescents. International Journal of Molecular Sciences, 2020, 21, 4739.	1.8	6
10	LIGHT/TNFSF14 regulates estrogen deficiencyâ€induced bone loss. Journal of Pathology, 2020, 250, 440-451.	2.1	15
11	Irisin serum levels are positively correlated with bone mineral status in a population of healthy children. Pediatric Research, 2019, 85, 484-488.	1.1	45
12	A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3088-3096.	1.8	41
13	Mechanisms Involved in Childhood Obesity-Related Bone Fragility. Frontiers in Endocrinology, 2019, 10, 269.	1.5	43
14	Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity. Frontiers in Immunology, 2019, 10, 1001.	2.2	24
15	Irisin and Bone: From Preclinical Studies to the Evaluation of Its Circulating Levels in Different Populations of Human Subjects. Cells, 2019, 8, 451.	1.8	41
16	An update on the role of RANKLâ€“RANK/osteoprotegerin and WNT-ÃŸ-catenin signaling pathways in pediatric diseases. World Journal of Pediatrics, 2019, 15, 4-11.	0.8	29
17	Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria. American Journal of Pathology, 2018, 188, 1059-1068.	1.9	20
18	Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems. Nephrology Dialysis Transplantation, 2018, 33, 65-75.	0.4	41

#	Article	IF	Citations
19	Impairment of Bone Remodeling in LIGHT/TNFSF14-Deficient Mice. Journal of Bone and Mineral Research, 2018, 33, 704-719.	3.1	16
20	Monoclonal antibodies for treating osteoporosis. Expert Opinion on Biological Therapy, 2018, 18, 149-157.	1.4	45
21	High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. Oncology Reports, 2018, 39, 2031-2039.	1.2	13
22	LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens. Frontiers in Immunology, 2018, 9, 2459.	2.2	20
23	Anatomy and Physiology of Skeletal Tissue: The Bone Cells. , 2018, , 1-23.		2
24	Deletion of the Transcription Factor PGC-1Î± in Mice Negatively Regulates Bone Mass. Calcified Tissue International, 2018, 103, 638-652.	1.5	17
25	Irisin and musculoskeletal health. Annals of the New York Academy of Sciences, 2017, 1402, 5-9.	1.8	112
26	Sclerostin stimulates angiogenesis in human endothelial cells. Bone, 2017, 101, 26-36.	1.4	20
27	Mechanisms of Altered Bone Remodeling in Multiple Myeloma. Clinical Reviews in Bone and Mineral Metabolism, 2017, 15, 151-161.	1.3	1
28	Integrated in vitro approaches to assess the bioaccessibility and bioavailability of silicon-biofortified leafy vegetables and preliminary effects on bone. In Vitro Cellular and Developmental Biology - Animal, 2017, 53, 217-224.	0.7	16
29	High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1174-1181.	1.8	67
30	Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies. Frontiers in Endocrinology, 2016, 7, 34.	1.5	35
31	Crosstalk Between Muscle and Bone Via the Muscle-Myokine Irisin. Current Osteoporosis Reports, 2016, 14, 132-137.	1.5	56
32	Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-Î±. Osteoporosis International, 2016, 27, 2355-2365.	1.3	52
33	Functions of vasopressin and oxytocin in bone mass regulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 164-169.	3.3	54
34	The effects of bone pÃ¢tÃ© on human osteoblasts cell cultures. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1399-1404.	0.8	1
35	Human Myeloma Cell Lines Induce Osteoblast Downregulation of CD99 Which Is Involved in Osteoblast Formation and Activity. Journal of Immunology Research, 2015, 2015, 1-13.	0.9	6
36	Skeleton and Glucose Metabolism: A Bone-Pancreas Loop. International Journal of Endocrinology, 2015, 2015, 1-7.	0.6	23

#	Article	IF	Citations
37	Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome. Bone, 2015, 81, 228-236.	1.4	31
38	Osteogenic differentiation of mesenchymal stem cells from dental bud: Role of integrins and cadherins. Stem Cell Research, 2015, 15, 618-628.	0.3	70
39	The myokine irisin increases cortical bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12157-12162.	3.3	372
40	CELLULAR MECHANISMS OF BONE REGENERATION: ROLE OF WNT-1 IN BONE-MUSCLE INTERACTION DURING PHYSICAL ACTIVITY39. Journal of Biological Regulators and Homeostatic Agents, 2015, 29, 39-45.	0.7	10
41	Osteoclastogenic Potential of Peripheral Blood Mononuclear Cells in Cleidocranial Dysplasia. International Journal of Medical Sciences, 2014, 11, 356-364.	1.1	5
42	Osteoporosis and obesity: Role of Wnt pathway in human and murine models. World Journal of Orthopedics, 2014, 5, 242.	0.8	56
43	Irisin Enhances Osteoblast DifferentiationIn Vitro. International Journal of Endocrinology, 2014, 2014, 1-8.	0.6	161
44	Treatment of osteoporosis in children with glucocorticoid-treated diseases. Expert Review of Endocrinology and Metabolism, 2014, 9, 525-534.	1.2	4
45	Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16502-16507.	3.3	63
46	Bone Matrix Proteins and Mineralization Process. , 2014, , 15-25.		5
47	Experimental Model for Studying the Involvement of Regulatory Cytotoxic T Cells in Bone Resorption. Methods in Molecular Biology, 2014, 1186, 269-281.	0.4	2
48	LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget, 2014, 5, 12950-12967.	0.8	52
49	Osteotropic Cancers: From Primary Tumor to Bone. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 94-102.	1.3	5
50	Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. International Journal of Cardiology, 2013, 169, 296-304.	0.8	77
51	Osteoblasts Display Different Responsiveness to TRAIL-Induced Apoptosis During Their Differentiation Process. Cell Biochemistry and Biophysics, 2013, 67, 1127-1136.	0.9	21
52	High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E546-E554.	1.8	41
53	Biological Characteristics of Dental Stem Cells for Tissue Engineering. Key Engineering Materials, 2013, 541, 51-59.	0.4	4
54	Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18644-18649.	3.3	120

#	Article	IF	Citations
55	Activation of the receptor activator of the nuclear factor-ÂB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures. European Journal of Cardio-thoracic Surgery, 2013, 44, e141-e147.	0.6	10
56	Glucocorticoid-Induced Osteoporosis in Children with 21-Hydroxylase Deficiency. BioMed Research International, 2013, 2013, 1-8.	0.9	39
57	The Role of TNF-Î±and TNF Superfamily Members in the Pathogenesis of Calcific Aortic Valvular Disease. Scientific World Journal, The, 2013, 2013, 1-10.	0.8	31
58	FSH and TSH in the Regulation of Bone Mass: The Pituitary/Immune/Bone Axis. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	33
59	Periodontal Disease: Linking the Primary Inflammation to Bone Loss. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	215
60	Genotypeâ€“phenotype correlation in Juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene. Endocrine, 2012, 42, 266-271.	1.1	23
61	Osteogenic Differentiation of Dental Follicle Stem Cells. International Journal of Medical Sciences, 2012, 9, 480-487.	1.1	65
62	Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochemical and Biophysical Research Communications, 2011, 411, 512-515.	1.0	47
63	TRAIL effect on osteoclast formation in physiological and pathological conditions. Frontiers in Bioscience - Elite, 2011, E3, 1154-1161.	0.9	14
64	Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Annals of the New York Academy of Sciences, 2011, 1237, 19-23.	1.8	77
65	Dental pulp stem cells: osteogenic differentiation and gene expression. Annals of the New York Academy of Sciences, 2011, 1237, 47-52.	1.8	82
66	Osteoclastogenesis and arthritis. Clinical and Experimental Medicine, 2011, 11, 137-145.	1.9	52
67	Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal, 2011, 1, e27-e27.	2.8	113
68	The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Annals of the New York Academy of Sciences, 2010, 1192, 298-302.	1.8	14
69	Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone Disease. , 2010, , 67-75.		0
70	Myeloma Cells Induce Osteoblast Suppression through Sclerostin Secretion. Blood, 2010, 116, 2961-2961.	0.6	4
71	Osteogenic properties of human dental pulp stem cells. Journal of Biological Regulators and Homeostatic Agents, 2010, 24, 167-75.	0.7	29
72	Oxytocin is an anabolic bone hormone. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7149-7154.	3.3	223

#	Article	IF	Citations
73	Microgravity during spaceflight directly affects in vitro osteoclastogenesis and bone resorption. FASEB Journal, 2009, 23, 2549-2554.	0.2	106
74	Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor-Î²B Ligand/Osteoprotegerin Imbalance. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2269-2276.	1.8	44
75	Osteoblast Apoptosis in Periodontal Disease: Role of TNF-Related Apoptosis-Inducing Ligand. International Journal of Immunopathology and Pharmacology, 2009, 22, 95-103.	1.0	40
76	Immunomodulation of Multiple Myeloma Bone Disease. Clinical Reviews in Bone and Mineral Metabolism, 2009, 7, 293-300.	1.3	4
77	Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D3 stimulation. Rheumatology International, 2009, 29, 667-672.	1.5	10
78	Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia, 2009, 23, 2139-2146.	3.3	38
79	l-Carnitine Fumarate and Isovaleryl-l-Carnitine Fumarate Accelerate the Recovery of Bone Volume/Total Volume Ratio after Experimetally Induced Osteoporosis in Pregnant Mice. Calcified Tissue International, 2008, 82, 221-228.	1.5	19
80	Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFÎ±, and IL-7 in anin vitromodel derived from human psoriatic arthritis. Journal of Pathology, 2007, 212, 47-55.	2.1	86
81	TRAIL Is Involved in Human Osteoclast Apoptosis. Annals of the New York Academy of Sciences, 2007, 1116, 316-322.	1.8	12
82	Synovial Fluid Fibroblasts and Lymphocytes Support the Osteoclastogenesis in Human Psoriatic Arthritis. Annals of the New York Academy of Sciences, 2007, 1117, 159-164.	1.8	10
83	A new titanium biofunctionalized interface based on poly(pyrrole-3-acetic acid) coating: proliferation of osteoblast-like cells and future perspectives. Journal of Materials Science: Materials in Medicine, 2007, 18, 1781-1789.	1.7	26
84	The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1623-1632.	2.2	53
85	Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL. Journal of Biological Regulators and Homeostatic Agents, 2007, 21, 105-14.	0.7	29
86	IL-7 Up-Regulates TNF-Î±-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor. PLoS ONE, 2006, 1, e124.	1.1	62
87	The Role of OPG/TRAIL Complex in Multiple Myeloma: The OPG/TRAIL Complex in an In Vitro Osteoclastogenesis Model Derived From Human Multiple Myeloma-Bone Disease. Annals of the New York Academy of Sciences, 2006, 1068, 334-340.	1.8	14
88	Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 2005, 106, 2472-2483.	0.6	289
89	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2005, 21, 207-218.	3.1	64
90	L-Carnitine and Isovaleryl L-Carnitine Fumarate Positively Affect Human Osteoblast Proliferation and Differentiation In Vitro. Calcified Tissue International, 2005, 76, 458-465.	1.5	39

#	Article	IF	Citations
91	Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clinical Rheumatology, 2005, 24, 527-534.	1.0	24
92	Increased Osteoclast Activity in the Presence of Increased Homocysteine Concentrations. Clinical Chemistry, 2005, 51, 2348-2353.	1.5	113
93	Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB Journal, 2005, 19, 1-24.	0.2	88
94	T Cells Support Osteoclastogenesis in an In Vitro Model Derived From Human Periodontitis Patients. Journal of Periodontology, 2005, 76, 1675-1680.	1.7	78
95	Interleukin-7 production by B lymphocytes affects the T cell-dependent osteoclast formation in an in vitro model derived from human periodontitis patients. International Journal of Immunopathology and Pharmacology, 2005, 18, 13-9.	1.0	18
96	Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Clinical Rheumatology, 2004, 23, 490-495.	1.0	31
97	T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood, 2004, 104, 3722-3730.	0.6	138
98	Gelatinase Levels in Male and Female Breast Cancer. Biochemical and Biophysical Research Communications, 2002, 292, 161-166.	1.0	25
99	Human osteoclasts express oxytocin receptor. Biochemical and Biophysical Research Communications, 2002, 297, 442-445.	1.0	58
100	Pathology of Idiopathic Encephaloceles into the Middle Ear. Orl, 2002, 64, 73-79.	0.6	8
101	Rat Hindlimb Unloading by Tail Suspension Reduces Osteoblast Differentiation, Induces IL-6 Secretion, and Increases Bone Resorption in Ex Vivo Cultures. Calcified Tissue International, 2002, 70, 176-185.	1.5	54
102	Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. Journal of Cell Science, 2002, 115, 2919-2929.	1.2	63
103	Breast Cancer Cell Line MDA-231 Stimulates Osteoclastogenesis and Bone Resorption in Human Osteoclasts. Biochemical and Biophysical Research Communications, 2000, 270, 1097-1100.	1.0	57
104	Synthesis, analytical characterization, and osteoblast adhesion properties on RGD-grafted polypyrrole coatings on titanium substrates. Journal of Biomaterials Science, Polymer Edition, 2000, 11, 1073-1083.	1.9	160
105	Response of Human Osteoblasts to Polymethylmetacrylate In Vitro. Calcified Tissue International, 1998, 62, 362-365.	1.5	57
106	Alendronate Reduces Adhesion of Human Osteoclast-like Cells to Bone and Bone Protein-Coated Surfaces. Calcified Tissue International, 1998, 63, 230-235.	1.5	81
107	Activation of Î±vÎ²3Integrin on Human Osteoclast-like Cells Stimulates Adhesion and Migration in Response to Osteopontin. Biochemical and Biophysical Research Communications, 1998, 249, 522-525.	1.0	57
108	The Osteoclast Cytoskeleton. Advances in Organ Biology, 1998, 5, 347-357.	0.1	0

#	Article	IF	Citations
109	Retinoic Acid Induces Cell Proliferation and Modulates Gelatinases Activity in Human Osteoclast-like Cell Lines. Biochemical and Biophysical Research Communications, 1996, 227, 47-52.	1.0	13
110	Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7644-7648.	3.3	202
111	Human osteoclast-like cells selectively recognize laminin isoforms, an event that induces migration and activates Ca2+ mediated signals. Journal of Cell Science, 1996, 109, 1527-1535.	1.2	16
112	Human osteoclast-like cells selectively recognize laminin isoforms, an event that induces migration and activates Ca2+ mediated signals. Journal of Cell Science, 1996, 109 (Pt 6), 1527-35.	1.2	0
113	Human Osteoclast-Like Cells from Giant Cell Tumors of Bone: A New Tool for Investigating Bone Resorption and Osteoclast Biology. Calcified Tissue International, 1995, 56, S24-S24.	1.5	5
114	Extracellular Ca2+ sensing is modulated by pH in human osteoclast-like cells in vitro. American Journal of Physiology - Cell Physiology, 1994, 267, C961-C968.	2.1	25
115	Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells.. Journal of Cell Biology, 1994, 127, 1149-1158.	2.3	168
116	Adhesion Properties and Integrin Expression of Cultured Human Osteoclast-like Cells. Experimental Cell Research, 1994, 212, 209-218.	1.2	47
117	New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumors of bone. Journal of Bone and Mineral Research, 1994, 9, 1013-1020.	3.1	42
118	Binding of osteopontin to the osteoclast integrin Î±vÎ²3. Osteoporosis International, 1993, 3, 132-135.	1.3	35
119	Immediate cell signal by bone-related peptides in human osteoclast-like cells. American Journal of Physiology - Cell Physiology, 1993, 265, C1289-C1297.	2.1	46
120	Histopathology of Spontaneous Brain Herniations Into the Middle Ear. Acta Oto-Laryngologica, 1992, 112, 328-333.	0.3	25
121	Osteoblast-osteoclast relationships in bone resorption: Osteoblasts enhance osteoclast activity in a serum-free co-culture system. Biochemical and Biophysical Research Communications, 1991, 179, 634-640.	1.0	29
122	Osteoclast cytosolic calcium, regulated by voltage-gated calcium channels and extracellular calcium, controls podosome assembly and bone resorption.. Journal of Cell Biology, 1990, 111, 2543-2552.	2.3	220